Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). Association ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results